PearceIP Blog

Read our latest updates & insights

Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.

UPC Court of Appeal Refuses Rehearing in Alexion’s Eculizumab Patent Infringement Actions Against Samsung Bioepis and Amgen

By Bioblast Editor | Jun 19, 2025

Read more

On 19 June 2025, the Unified Patent Court (UPC) Court of Appeal issued decisions refusing two rehearing applications by Alexion Pharmaceuticals in proceedings it had brought seeking preliminary injunctions against Amgen and Samsung Bioepis in relation to the sale of their e...
MSD’s Clesrovimab Accepted for Review Alongside Expanded Indication for GSK’s Nucala® (Mepolizumab)

By Bioblast Editor | Jun 19, 2025

Read more

On 19 June 2025, Australia’s Therapeutic Goods Administration (TGA) updated its online list of prescription medicines for evaluation for March, April and May 2025.

Among the applications to be reviewed is MSD’s clesrovimab (MK-1654, approved on 9 June 2025 as Enflons...
Pearce IP Leaders Recognised in WIPR Leaders 2025

By Pearce IP | Jun 19, 2025

Read more

Four Pearce IP leaders have been included in World IP Review (WIPR) Leaders 2025. WIPR Leaders provides a research driven global guide to the top intellectual property lawyers acro...
Pearce IP is the DEI: Outstanding Firm - 2025 Chambers Asia-Pacific & Greater China

By Pearce IP | Jun 19, 2025

Read more

We are thrilled to share that Pearce IP was awarded DEI: Outstanding Firm at the Chambers Asia-Pacific and Greater China Region Awards 2025 gala in Singapore on 30 May.
For ...
Pearce IP BioBlast® for the week ending 13 June 2025

By Naomi Pearce, Chantal Savage, Nathan Kan | Jun 17, 2025

Read more

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 13 June 2025 are set out below:...
Regeneron Files New US BPCIA Complaint Against Amgen for Pavblu™, Eylea® Biosimilar

By Bioblast Editor | Jun 17, 2025

Read more

On 17 June 2025, Regeneron filed a new BPCIA complaint against Amgen in the United States District Court for the Central District of California, asserting that Amgen’s Pavblu™/ABP 938 (aflibercept) infringes US 12,331,099, which claims an ophthalmic formulation of afliberce...
Pearce IP Ranked by MIP for Trade Mark Prosecution 2025

By Pearce IP | Jun 16, 2025

Read more

Pearce IP has been recognised for the first time by Managing IP Stars for trade mark prosecution in its 2025 Trade Mark rankings.
In addition to Pearce IP’s existing ranking f...
6 Pearce IP Lawyers/Attorneys Recognised by 2025 MIP IP STARS

By Pearce IP | Jun 16, 2025

Read more

We are thrilled to announce that 6 Pearce IP patent professionals have again been recognised by Managing IP in the 2025 MIP IP STARS, a leading global guide to the top intellectual ...
FDA Approves New Presentation of Celltrion’s Ustekinumab Biosimilar

By Bioblast Editor | Jun 16, 2025

Read more

On 16 June 2025, Celltrion announced that the FDA has approved a new single-dose 45mg/0.5mL subcutaneous injection of Steqeyma® (CT-P43), biosimilar to J&J/Janssen’s Stelara® (ustekinumab). The new presentation is approved for the treatment of paediatric patients aged ...
German Court Rules Samsung Bioepis/Biogen’s Adalimumab Biosimilar Infringes Fresenius Formulation Patent

By Bioblast Editor | Jun 16, 2025

Read more

On 16 June 2025, Korea Biomedical Review reported that the Dusseldorf Higher Regional Court ruled that Samsung Bioepis/Biogen’s Imraldi®, biosimilar to AbbVie’s Humira® (adalimumab), infringes a formulation patent held in Germany by Fresenius Kabi. The Fresenius patent, E...